ctDNA for the Evaluation and Management of EGFR-Mutant Non-Small Cell Lung Cancer
Simple Summary Lung cancer patients with a specific gene mutation often undergo tissue
biopsies to guide treatment. But what if a simple blood test could do the same? This review …
biopsies to guide treatment. But what if a simple blood test could do the same? This review …
Clinical significance of TP53 alterations in advanced NSCLC patients treated with EGFR, ALK and ROS1 tyrosine kinase inhibitors: An update
J Moes-Sosnowska, A Szpechcinski… - Tumor …, 2023 - content.iospress.com
The development of targeted therapies for non-small cell lung cancer (NSCLC), such as the
epidermal growth factor receptor (EGFR), anaplastic lymphoma receptor tyrosine kinase …
epidermal growth factor receptor (EGFR), anaplastic lymphoma receptor tyrosine kinase …
Cetuximab-based PROteolysis targeting chimera for effectual downregulation of NSCLC with varied EGFR mutations
Abstract PROteolysis Targeting Chimeras (PROTACs) showed tremendous therapeutic
potential in degrading several oncoproteins including undruggable proteins. PROTACs are …
potential in degrading several oncoproteins including undruggable proteins. PROTACs are …
The activity of a PI3K δ-sparing inhibitor, MEN1611, in non-small cell lung cancer cells with constitutive activation of the PI3K/AKT/mTOR pathway
G Papoff, D Presutti, V Fustaino, A Parente… - Frontiers in …, 2023 - frontiersin.org
Background Lung cancer remains the leading cause of cancer-related death worldwide.
Targeted therapies with tyrosine kinase inhibitors (TKIs) result in improvement in survival for …
Targeted therapies with tyrosine kinase inhibitors (TKIs) result in improvement in survival for …
[HTML][HTML] Response to osimertinib in a colorectal cancer patient with an EGFR T790M mutation: A case report
B Buzard, L Douglass, B Gustafson… - World Journal of …, 2023 - ncbi.nlm.nih.gov
BACKGROUND Although common in lung cancer, somatic epidermal growth factor receptor
(EGFR) mutations are rarely found in colorectal cancer, occurring in approximately 3% of …
(EGFR) mutations are rarely found in colorectal cancer, occurring in approximately 3% of …
[HTML][HTML] Epithelial-mesenchymal transition is associated with osteopontin-induced EGFR‑TKI resistance in EGFR mutant non-small cell lung cancer
J Chen, L Shi, Y Qian, Y Jin, N Dong… - Journal of Thoracic …, 2023 - ncbi.nlm.nih.gov
Background Resistance restricts the long-term therapeutic efficacy of epidermal growth
factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) in the treatment of non-small cell lung …
factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) in the treatment of non-small cell lung …
The predictive value of serum tumor markers for EGFR mutation in non-small cell lung cancer patients with non-stage IA
W Du, T Qiu, H Liu, A Liu, Z Wu, X Sun, Y Qin, W Su… - Heliyon, 2024 - cell.com
Objective The predictive value of serum tumor markers (STMs) in assessing epidermal
growth factor receptor (EGFR) mutations among patients with non-small cell lung cancer …
growth factor receptor (EGFR) mutations among patients with non-small cell lung cancer …
Anti-cancer effects of bis-oxidized thiopyran derivatives on non-small cell lung cancer: rational design, synthesis, and activity evaluation
H Zhang, C Chu, L Long, P Zheng, W Zhu - New Journal of Chemistry, 2024 - pubs.rsc.org
The development of small molecule anti-tumor drugs has emerged as a promising strategy
for cancer treatment, meanwhile the EGFR is associated with tumor formation and …
for cancer treatment, meanwhile the EGFR is associated with tumor formation and …
The Role of SPEN Mutations as Predictive Biomarkers for Immunotherapy Response in Colorectal Cancer: Insights from a Retrospective Cohort Analysis
Y Dong, S Ye, H Li, J Li, R Liu, Y Zhu - Journal of Personalized Medicine, 2024 - mdpi.com
Background: Colorectal cancer (CRC) is the leading cause of cancer deaths, and treatment,
especially in the metastatic stage, is challenging. Immune checkpoint inhibitors (ICIs) have …
especially in the metastatic stage, is challenging. Immune checkpoint inhibitors (ICIs) have …
[HTML][HTML] Current status of molecular diagnostics for lung cancer
EN Imyanitov, EV Preobrazhenskaya… - Exploration of Targeted …, 2024 - ncbi.nlm.nih.gov
The management of lung cancer (LC) requires the analysis of a diverse spectrum of
molecular targets, including kinase activating mutations in EGFR, ERBB2 (HER2), BRAF …
molecular targets, including kinase activating mutations in EGFR, ERBB2 (HER2), BRAF …